Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCN4 | Q9Y3Q4 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 6/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.33 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.33 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15180368 | 0.85 | HCN4 (0.42) | HCN4MAPTCYP3A4CHRM2SLC6A4 | |
| SCHEMBL12462421 | 0.82 | SMN1; SMN2 (0.40) | HCN4MAPTCYP3A4CHRM2SLC6A4 | |
| SCHEMBL333182 | 0.82 | HCN4 (0.58) | HCN4MAPTCYP3A4CHRM2SLC6A4 | |
| Hydrochloric Acid SCHEMBL10597759 | 0.81 | CYP3A4 (0.59) | HCN4MAPTCYP3A4CHRM2SLC6A4 | |
| SCHEMBL15044202 | 0.81 | HCN4 (0.39) | HCN4MAPTCYP3A4CHRM2SLC6A4 | |
| SCHEMBL15044211 | 0.78 | HCN4 (0.39) | HCN4MAPTCYP3A4CHRM2SLC6A4 | |
| SCHEMBL8270902 | 0.77 | HCN4 (0.35) | HCN4MAPTCYP3A4CHRM2SLC6A4 | |
| SCHEMBL8373923 | 0.77 | KMT2A (0.36) | HCN4MAPTCYP3A4CHRM2SLC6A4 | |
| SCHEMBL8370922 | 0.75 | HCN4 (0.61) | HCN4MAPTCYP3A4CHRM2SLC6A4 | |
| SCHEMBL8372895 | 0.75 | HCN4 (0.61) | HCN4MAPTCYP3A4CHRM2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119794-B2 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2012-02-21 | — | — | US | disclosed |
| EP-2241553-B1 | Process for the synthesis of ivabradine and its pharmaceutically acceptable acid addition salts | SERVIER LAB (FR) | 2011-07-20 | — | — | EP | disclosed |
| EP-2241553-A1 | Process for the synthesis of ivabradine and its pharmaceutically acceptable acid addition salts | Les Laboratoires Servier (FR) | 2010-10-20 | — | — | EP | disclosed |
| WO-2010112705-A1 | NOVEL METHOD FOR THE SYNTHESIS OF IVABRADINE AND THE ADDITION SALTS THEREOF WITH A PHARMACEUTICALLY ACCEPTABLE ACID | LES LABORATOIRES SERVIER (FR) | 2010-10-07 | — | — | WO | disclosed |
| US-20100249398-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | LES LABORATOIRES SERVIER (FR) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249398-A1 | Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid | CYP4F2, CYP2F1, CYP2D6 | HCN4 37/4885MAPT 4588/4885CYP3A4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.